New Choices. New Possibilities.
huvepharma.us
877-994-4883
MLV BVD Protection: Viral Strains Matter
• Research indicates that MLV vaccines containing BVD Type
1a Singer strain stimulates cross protective antibodies to
BVD Type 1b in calves.
1
• Vaccines containing Singer strain induced higher antibody
titers to BVD Type 1b than those containing NADL strain.
1
RESPIVax™ MLV Manufacturing
• RESPIVax 5 and RESPIVax 3 MLV vaccines were
developed with rigorous emphasis on design
and quality control including next generation
genetic sequencing for maintenance of viral
master seed purity to ensure a consistent, safe,
and effective product.
• Extraneous agent
testing exceeds USDA
Center for Veterinary
Biologics standards and
requirements.
• RESPIVax is manufactured
at high levels of quality
assurance and animal
safety.
Vaccine Quality and Production
RESP092020009
HP1126
INDICATIONS: This product has been shown to be effective for the vaccination of healthy cattle five months of age or older against
Infectious Bovine Rhinotracheitis, Bovine Viral Diarrhea Virus Type 1a, Bovine Viral Diarrhea Virus Type 2, Parainfluenza3 Bovine
Respiratory Syncytial Virus, Mannheimia haemolytica and Pasteurella multocida. Duration of Immunity for this product has not been
determined. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.
1
Fulton RW, Cook BJ, Payton ME, Burge LJ, Step DL. Immune response to bovine viral diarrhea virus (BVDV) vaccines detecting antibodies to BVDV
subtypes 1a, 1b, 2a, and 2c. Vaccine. 2020 Jan 26;22(5-6):643-9.
RESPIVax 5 MLV viral fractions include the following:
IBR Cooper strain, BVD Type 1a Singer, BVD Type 2 125,
PI3 Reisinger strain, BRSV N-375 strain.
Pulmo-Guard
®
PH-M
• Pulmo-Guard PH-M was reformulated with a smoother
less reactive aqueous base adjuvant with the same
safety, efficacy and excellent syringeability as previous
formulations.
• Manufacturing process modification implemented in 2020
have reduced the endotoxin content in Pulmo-Guard PH-M
when compared to serials produced in 2018 and 2019.
• PH-M is a bacterin/toxoid which
elicits a robust anti-leukotoxin
antibody immune response while
minimizing potential for
negative effects.
